cytochrome P450 family 2 subfamily C member 19
Last updated 28 Sept 2020
Meets Patient’s editorial guidelines
- DownloadDownload
- Share
- Language
- Discussion
- Ask Patient
- Audio Version
- Add to preferred sources on Google
The CYP2C19 gene is a member of the cytochrome P450 gene family. Enzymes produced from cytochrome P450 genes are involved in the formation and breakdown (metabolism) of various molecules and chemicals within cells. The CYP2C19 gene provides instructions for making an enzyme that is found primarily in liver cells in a cell structure called the endoplasmic reticulum, which is involved in protein processing and transport.
Video picks for GenesVideo library
Normal function
The CYP2C19 gene is a member of the cytochrome P450 gene family. Enzymes produced from cytochrome P450 genes are involved in the formation and breakdown (metabolism) of various molecules and chemicals within cells. The CYP2C19 gene provides instructions for making an enzyme that is found primarily in liver cells in a cell structure called the endoplasmic reticulum, which is involved in protein processing and transport.
The CYP2C19 enzyme plays a role in the processing or metabolizing of at least 10 percent of commonly prescribed drugs, including a drug called clopidogrel (also known as Plavix). Clopidogrel is an antiplatelet drug, which means that it prevents blood cells called platelets from sticking together (aggregating) and forming blood clots. The CYP2C19 enzyme converts clopidogrel to its active form, which is necessary for the drug to function in the body. The active drug then stops (inhibits) a receptor protein known as P2RY12 that is found on the surface of platelets. During clot formation, the P2RY12 receptor protein helps platelets cluster together to form a clot in order to seal off damaged blood vessels and prevent blood loss.
Conditions referring to this gene or chromosome
Other names
(R)-limonene 6-monooxygenase
(S)-limonene 6-monooxygenase
(S)-limonene 7-monooxygenase
CPCJ
CYP2C
CYPIIC17
CYPIIC19
cytochrome P-450 II C
cytochrome P450 2C19 precursor
cytochrome P450, subfamily IIC (mephenytoin 4-hydroxylase), polypeptide 19
cytochrome P450-11A
cytochrome P450-254C
flavoprotein-linked monooxygenase
mephenytoin 4'-hydroxylase
mephenytoin 4-hydroxylase
microsomal monooxygenase
P450C2C
P450IIC19
S-mephenytoin 4-hydroxylase
xenobiotic monooxygenase
Patient picks for Genes

COVID-19
When will I get my COVID-19 vaccine?
With news that the COVID-19 vaccine has been offered to to government's top 4 priority groups in the UK, the prospect of vaccination available to all is becoming more real. Here we explore which groups have been offered vaccination, why they were prioritised and who comes next.
by Dr Sarah Jarvis

COVID-19
The latest treatments for COVID-19
As England continues through its second coronavirus lockdown and infection numbers across the globe are climbing, researchers are working tirelessly to find the best treatment for COVID-19. There are currently hundreds of treatments being trialled in a bid to curb the spread of the virus and save lives.
by Andrea Downey

COVID-19
How does the new 90-minute COVID-19 test work?
Two new 90-minute tests for COVID-19 are being rolled out ahead of winter. So why might rapid testing make so much difference and can these tests deliver on what's being promised?
by Abi Millar

Infections
Should you and your family get the meningitis vaccination?
Meningitis is a serious condition, but it is not caused by one bug - bacteria, viruses and even fungi can lead to infection. Thankfully, there are meningitis vaccinations available.
by Danny Chadburn

COVID-19
COVID-19: can I get tested for coronavirus?
Right from the beginning of the coronavirus outbreak, testing has been front and centre of many countries' responses to the pandemic. As cases of COVID-19 increase, the UK government plans to offer new tests to patients and healthcare workers across the country.
by Milly Evans

COVID-19
Will we need a COVID-19 booster vaccine every year?
COVID-19 booster vaccines are essential, giving you longer-term protection against getting seriously ill from the disease. And with cases of infection and hospital admissions on the rise in the UK, those who are eligible for the vaccine are being urged to have their top-up jab. But will we always need periodic boosting against COVID-19, like we do against the flu?
by Lydia Smith
Related patient information and medicines

Patient information leaflet
Can I take Black cohosh and Vitamin C together?
I... Why this happens Black cohosh and vitamin C are processed by the body through different pathways. Vitamin C is a water-soluble vitamin that does not significantly interfere with the liver enzymes (such as the Cytochrome P450 system) that process black cohosh. Additionally, they do not have overlapping effects that would cause a dangerous.

Patient information leaflet
Can I take Black cohosh and Glucosamine together?
Why this happens These two substances are processed by the body through different pathways. Glucosamine is an amino sugar used by the body to build cartilage, while black cohosh is a herbal remedy that primarily affects hormonal pathways or neurotransmitters. They do not compete for the same enzymes in the liver (such as the Cytochrome P450.

Patient information leaflet
Can I take Glucosamine and St John's wort together?
T... It is generally considered safe to take these two supplements together. Why this happens Glucosamine is primarily used by the body to build cartilage and does not significantly affect the liver enzymes (Cytochrome P450) that St John's wort is known to influence. St John's wort works by altering brain chemicals and speeding up the breakdown of.

Patient information leaflet
Can I take Promethazine and Vitamin D3 together?
It is generally considered sa... Why this happens Promethazine is an antihistamine processed primarily by the liver's cytochrome P450 enzymes, while vitamin D3 is a fat-soluble vitamin that undergoes a different metabolic pathway (hydroxylation in the liver and kidneys). They do not interfere with each other's absorption, metabolism, or effects in.

Patient information leaflet
Polycystic kidney disease
You need two faulty genes to develop this condition. You get one faulty gene from each parent (who will be well but will be 'carriers' of one faulty gene each). Non-hereditary polycystic kidney disease In about 1 in 10 people who develop polycystic kidney disease, the faulty gene is a new mutation in the affected person. So, there are no other.

Patient information leaflet
Diabetes in children
Diabetes is a lifelong condition that sometimes starts in childhood. As a result of ongoing research, our understanding of diabetes has greatly improved and there are now extensive support and treatments available for diabetes. About 9 in 10 children and young people in the UK who have diabetes will have type 1 diabetes, and 1 in 10 will have type.
Further reading and references
- cytochrome P450 family 2 subfamily C member 19; MedlinePlus, National Library of Medicine.
- Hirota T, Eguchi S, Ieiri I. Impact of genetic polymorphisms in CYP2C9 and CYP2C19 on the pharmacokinetics of clinically used drugs. Drug Metab Pharmacokinet. 2013;28(1):28-37. doi: 10.2133/dmpk.dmpk-12-rv-085. Epub 2012 Nov 20.
- Scott SA, Sangkuhl K, Shuldiner AR, Hulot JS, Thorn CF, Altman RB, Klein TE. PharmGKB summary: very important pharmacogene information for cytochrome P450, family 2, subfamily C, polypeptide 19. Pharmacogenet Genomics. 2012 Feb;22(2):159-65. doi: 10.1097/FPC.0b013e32834d4962.
- Scott SA, Sangkuhl K, Stein CM, Hulot JS, Mega JL, Roden DM, Klein TE, Sabatine MS, Johnson JA, Shuldiner AR; Clinical Pharmacogenetics Implementation Consortium. Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update. Clin Pharmacol Ther. 2013 Sep;94(3):317-23. doi: 10.1038/clpt.2013.105. Epub 2013 May 22.
- Society for Cardiovascular Angiography and Interventions; Society of Thoracic Surgeons; Writing Committee Members; Holmes DR Jr, Dehmer GJ, Kaul S, Leifer D, O'Gara PT, Stein CM. ACCF/AHA Clopidogrel clinical alert: approaches to the FDA "boxed warning": a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the American Heart Association. Circulation. 2010 Aug 3;122(5):537-57. doi: 10.1161/CIR.0b013e3181ee08ed. Epub 2010 Jun 28. No abstract available.
- Uppugunduri CR, Daali Y, Desmeules J, Dayer P, Krajinovic M, Ansari M. Transcriptional regulation of CYP2C19 and its role in altered enzyme activity. Curr Drug Metab. 2012 Oct;13(8):1196-204. doi: 10.2174/138920012802850146.
Share your thoughts or experiences with others in our patient communities.
Sign up to the Patient newsletter
Your weekly dose of clear, trustworthy health advice - written to help you feel informed, confident and in control.
By subscribing you accept our Privacy Policy. You can unsubscribe at any time. We never sell your data.

